Innovation in Biomanufacturing Plants


10th November 2020 | 08:00 AM GMT/ 16:00 PM CST | Hang Zhou, Ph.D., Vice President, Head of Cell Culture Process Development Biologics and Bioprocess Dept. at WuXi Biologics |BOOK FREE SEAT FOR THIS WEBINAR

Biopharmaceutical plants will look different in the future. Agility and flexibility for rapidly changing product portfolios, single-use technologies, continuous manufacturing, small batch manufacturing, personalised medicine manufacturing will not only change the face of a plant but will also require other logistics models. Hang will explain WuXi Biologics’ approach to biological facilities of the future.

Presented by Hang Zhou, Ph.D., Vice President, Head of Cell Culture Process Development Biologics and Bioprocess Dept. at WuXi Biologics

Dr. Hang Zhou studied Biotechnology and received his PhD in Chemical Engineering from Massachusetts Institute of Technology. He has more than 10 years of experience in cell culture process development, in particular continuous processing.
At WuXi Biologics Hang leads a team in continuous cell culture process development for biologics. His team successfully overcame multiple challenges accompanied with intensified perfusion culture, and developed WuXiUP, a proprietary biologics production platform with Ultra-high Productivity. With WuXiUP the cell culture has achieved productivity of 2.5g/L/day and 51g/L bioreactor volume in a 20-day process for an Fc-fusion protein. The Platform enables almost any biologics, including mAbs and fusion proteins, to be manufactured at ultra-high productivity. The intensified and continuous cell culture process can be rapidly developed or converted from traditional fed-batch process with excellent scalability and robustness. It’s also couples with continuous column chromatography, which enables a similar purification yield of traditional purification process.
Prior to joining WuXi Biologics, Dr. Zhou worked for Commercial Cell Culture Development at SANOFI GENZYME and led efforts in the next-generation perfusion platform development.

Followed by John Bonham-Carter. Product Line Leader, Cell Culture & Clarification Business, Repligen

John joined Repligen during 2014 as part of the acquisition of Refine Technology where he was Vice President. He has developed and worked with different upstream technologies and, most recently, has propelled the XCell™ ATF System to become the dominant industry technology in continuous culture. Previously, he has founded or co-founded multiple companies in several countries in industries from newspapers to bioprocessing. John advises and speaks on small business coaching and entrepreneurship. John is a regular international speaker on bioprocessing. He is the editor of two editions of a book introducing Continuous Bioprocessing.

Sponsored by Repligen

Inspiring advances in bioprocessing, Repligen is a technology leader in bioprocess filtration, pre-packed chromatography and Protein A ligands development. Propelled by a culture of innovation and collaboration, and with a focus on cost and process efficiencies, our people and our technologies help meet critical bioproduction demands worldwide. Named one of the fastest growing biotech companies in the USA, Repligen is headquartered in Boston, MA with major manufacturing sites in Massachusetts, California, Sweden, and Germany.


We will not sell your information to a third party. See our Privacy Policy